SAB Biotherapeutics Analyst Ratings
SAB Biotherapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/21/2023 | 173.93% | HC Wainwright & Co. | $4 → $2 | Maintains | Buy |
| 06/21/2023 | 447.87% | HC Wainwright & Co. | → $4 | Reiterates | Buy → Buy |
| 06/16/2023 | 447.87% | HC Wainwright & Co. | → $4 | Reiterates | Buy → Buy |
| 06/15/2023 | 310.9% | Chardan Capital | → $3 | Reiterates | Buy → Buy |
| 05/17/2023 | 447.87% | HC Wainwright & Co. | → $4 | Reiterates | Buy → Buy |
| 04/27/2023 | 310.9% | Chardan Capital | → $3 | Reiterates | → Buy |
| 04/13/2023 | 447.87% | HC Wainwright & Co. | → $4 | Reiterates | → Buy |
| 04/03/2023 | 447.87% | HC Wainwright & Co. | → $4 | Reiterates | → Buy |
| 11/29/2022 | 447.87% | HC Wainwright & Co. | → $4 | Initiates Coverage On | → Buy |
| 08/11/2022 | 310.9% | Chardan Capital | $7 → $3 | Maintains | Buy |
| 05/13/2022 | 858.77% | Chardan Capital | $10 → $7 | Maintains | Buy |
| 04/01/2022 | 1269.67% | Chardan Capital | $17 → $10 | Maintains | Buy |
| 11/05/2021 | 2228.44% | Chardan Capital | → $17 | Initiates Coverage On | → Buy |
| 11/02/2021 | 3050.25% | Baird | → $23 | Initiates Coverage On | → Outperform |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 2023年08月21日 | 173.93% | HC Wainwright公司 | $4→$2 | 維護 | 買 |
| 2023年6月21日 | 447.87% | HC Wainwright公司 | →$4 | 重申 | 購買→購買 |
| 06/16/2023 | 447.87% | HC Wainwright公司 | →$4 | 重申 | 購買→購買 |
| 2023/06/15 | 310.9% | 查爾丹資本 | →$3 | 重申 | 購買→購買 |
| 2023年05月17日 | 447.87% | HC Wainwright公司 | →$4 | 重申 | 購買→購買 |
| 04/27/2023 | 310.9% | 查爾丹資本 | →$3 | 重申 | →購買 |
| 04/13/2023 | 447.87% | HC Wainwright公司 | →$4 | 重申 | →購買 |
| 04/03/2023 | 447.87% | HC Wainwright公司 | →$4 | 重申 | →購買 |
| 2022年11月29日 | 447.87% | HC Wainwright公司 | →$4 | 開始承保 | →購買 |
| 2022年08月11日 | 310.9% | 查爾丹資本 | $7→$3 | 維護 | 買 |
| 2022年05月13日 | 858.77% | 查爾丹資本 | $10→$7 | 維護 | 買 |
| 04/01/2022 | 1269.67% | 查爾丹資本 | $17→$10 | 維護 | 買 |
| 2021年11月05日 | 2228.44% | 查爾丹資本 | →$17 | 開始承保 | →購買 |
| 11/02/2021 | 3050.25% | 貝爾德 | →$23 | 開始承保 | →跑贏大盤 |
What is the target price for SAB Biotherapeutics (SABS)?
SAB生物療法(SABS)的目標價格是多少？
The latest price target for SAB Biotherapeutics (NASDAQ: SABS) was reported by HC Wainwright & Co. on August 21, 2023. The analyst firm set a price target for $2.00 expecting SABS to rise to within 12 months (a possible 173.93% upside). 9 analyst firms have reported ratings in the last year.
納斯達克(SAB：SABS)的最新目標價是由HC Wainwright&Co.於2023年8月21日報道的。這家分析公司將目標價定為2美元，預計SABS將在12個月內上漲(漲幅可能為173.93)。去年有9家分析公司公佈了評級。
What is the most recent analyst rating for SAB Biotherapeutics (SABS)?
SAB BioTreateutics(SABS)最近的分析師評級是多少？
The latest analyst rating for SAB Biotherapeutics (NASDAQ: SABS) was provided by HC Wainwright & Co., and SAB Biotherapeutics maintained their buy rating.
納斯達克(Sequoia Capital：SABS)的最新分析師評級由HC Wainwright&Co.提供，SAB生物治療公司維持買入評級。
When is the next analyst rating going to be posted or updated for SAB Biotherapeutics (SABS)?
SAB BioTreateutics(SABS)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of SAB Biotherapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for SAB Biotherapeutics was filed on August 21, 2023 so you should expect the next rating to be made available sometime around August 21, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括查閱公共財務報表，與SAB BioTreateutics的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。SAB生物療法的上一次評級是在2023年8月21日提交的，所以你應該預計下一次評級將在2024年8月21日左右的某個時候提供。
Is the Analyst Rating SAB Biotherapeutics (SABS) correct?
分析師對SAB生物療法(SABS)的評級正確嗎？
While ratings are subjective and will change, the latest SAB Biotherapeutics (SABS) rating was a maintained with a price target of $4.00 to $2.00. The current price SAB Biotherapeutics (SABS) is trading at is $0.73, which is out of the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的SAB BioTreateutics(SABS)評級維持不變，目標價在4.00美元至2.00美元之間。SAB BioTreateutics(SABS)目前的股價為0.73美元，超出了分析師的預測區間。